Pure Biologics Spólka Akcyjna - Asset Resilience Ratio
Pure Biologics Spólka Akcyjna (PUR) has an Asset Resilience Ratio of 6.13% as of September 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Pure Biologics Spólka Akcyjna (PUR) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2022)
This chart shows how Pure Biologics Spólka Akcyjna's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see PUR total assets.
Liquid Assets Composition Over Time
This chart breaks down Pure Biologics Spólka Akcyjna's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Pure Biologics Spólka Akcyjna long-term investment allocation to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł3.99 Million | 6.13% |
| Total Liquid Assets | zł3.99 Million | 6.13% |
Asset Resilience Insights
- Limited Liquidity: Pure Biologics Spólka Akcyjna maintains only 6.13% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Pure Biologics Spólka Akcyjna Industry Peers by Asset Resilience Ratio
Compare Pure Biologics Spólka Akcyjna's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Pulike Biological Engineering
SHG:603566 |
Biotechnology | 17.82% |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 14.00% |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5 |
Biotechnology | 41.67% |
|
Upstream Bio, Inc.
NASDAQ:UPB |
Biotechnology | 64.70% |
Annual Asset Resilience Ratio for Pure Biologics Spólka Akcyjna (2021–2022)
The table below shows the annual Asset Resilience Ratio data for Pure Biologics Spólka Akcyjna.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 14.90% | zł4.92 Million ≈ $1.35 Million |
zł33.01 Million ≈ $9.08 Million |
-41.79pp |
| 2021-12-31 | 56.69% | zł26.75 Million ≈ $7.36 Million |
zł47.19 Million ≈ $12.99 Million |
-- |
About Pure Biologics Spólka Akcyjna
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFß1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the aVß8 integrin. The company was founded… Read more